Kiran Mazumdar-Shaw and Falguni Nayar: 3 Lessons Indian Women Entrepreneurs Teach Us About Starting Late

Chanakya wrote in the Arthashastra that the wise person profits where others see only risk. Falguni Nayar spotted exactly that kind of gap in 2012. Organised beauty retail in India barely existed. Department store cosmetics counters were chaotic, mall kiosks stocked only a few international brands, and online shopping for beauty products was treated as a fringe behaviour. Nayar, a former investment banker at Kotak Mahindra, had spent decades reading markets. She recognised that Indian women were already spending on beauty, they just had nowhere reliable to do it. Nykaa launched not as a technology bet but as a curation bet: the right products, authenticated, delivered. The age at which she started, 49, was irrelevant to the logic of the gap. The gap was real regardless of who spotted it.

Kiran Mazumdar-Shaw did the same thing in 1978, in a different sector. Enzymes for industrial use were being imported at high cost. She had the biochemistry training and a contact in Ireland willing to provide the technical knowledge. Biocon started in a rented Bangalore garage with a capital of Rs 10,000. The gap was not glamorous. It was industrial fermentation. But it was uncontested, and she knew it better than anyone who might have competed with her.

The pattern: both founders chose domains where the absence of serious competition was itself the signal. Not because no one had tried, because the domain looked too unglamorous, too niche, or too risky for established players to bother. Late starters have one structural advantage here. They have usually spent enough time in an industry to know where the respectable money refuses to go.

Neither Nayar nor Mazumdar-Shaw scaled fast in their first years. Nykaa took nearly four years to turn profitable, and Nayar resisted pressure to expand categories recklessly. Biocon spent its first decade building fermentation expertise and regulatory credibility before it touched the pharmaceutical market that would eventually make it a global name. This is not caution for its own sake. It is sequencing.

Chanakya's Arthashastra returns repeatedly to the idea that a leader who moves before their base is consolidated loses both the advance and the base. The application to a startup is direct: scale without product credibility is just a faster way to fail publicly. Mazumdar-Shaw understood this acutely because she had no margin for error. Investors in the late 1970s and 1980s were openly skeptical of a woman running a biotech company. She could not afford a visible stumble. So she did not stumble. She built the science first, the reputation second, and the scale third, in that order.

For any Indian founder starting a business in their 40s or later, this sequencing is actually easier, not harder. You have fewer investors demanding hockey-stick growth in year one. You have more professional credibility to draw on. You have a clearer read on which customers are real and which are noise. The founders who start late and fail tend to rush scale to prove they still have time. The ones who succeed treat the slower early phase as an asset.

Falguni Nayar has spoken publicly about being told, repeatedly, that she was too old to start a company. She used that skepticism as a filter. Anyone who led with her age as a disqualifier was not someone whose opinion about market timing she needed to weight heavily. The dismissal told her something useful about the dismisser.

Mazumdar-Shaw faced a version of this earlier and harder. Banks refused her loans. Employees quit because they did not want to work for a woman. She has described those early years not as a confidence story but as a persistence story, showing up to the same meetings, with the same data, until the data became undeniable. Her age at founding, 25, was not the obstacle. Her gender was. But the mechanism was identical: external skepticism as a sorting tool for who was actually worth persuading.

What both founders understood is that the late start, or the unconventional start, carries a narrative that serious investors and customers eventually find compelling. A 49-year-old banker who walks away from a senior role to build a beauty company from scratch is not hedging. That is conviction. It reads differently than a 25-year-old with nothing to lose. Nykaa's IPO in 2021 valued the company at over Rs 1 lakh crore. The story of the founder's age was part of why the market paid attention.

The lesson is not to perform the late-start narrative. It is to stop apologising for it. The apology signals doubt. The absence of apology signals that you have already done the math and you like the odds.